Source: International Congress 2014 – Genes and environment in asthma and COPD
Disease area: Airway diseases

Abstract

Background. Airway inflammation is a key component of asthma that depends on the interplay of multiple genes. However, the association between health outcomes and genetic factors is usually evaluated by testing each candidate gene variant individually.Aim. To simultaneously assess the association of symptom severity with tag-SNPs located in inflammation-related genes and the FeNO level.Methods. In Verona (Italy), 327 asthmatics (aged 20-64) were identified from the general population in the GEIRD study (2008/2010). Individuals underwent a clinical interview, blood sampling for genotyping, and the measurement of FeNO (200 ml/s). SNPs in the CHI3L1, RAD50/IL4/IL5/IL13, IL33, and MS4A2 gene regions were genotyped by a custom GoldenGate Genotyping Assay. A symptom severity score (SSS) was computed by a multiple correspondence analysis on the basis of asthma-like symptoms, asthma attacks and hospitalization in the past year. The association of the SSS with SNPs and FeNO was assessed by a SEM. SNPs were summarised by a latent variable; atopy, gender, smoking habits and ICS use in the past year were considered as potential confounders.Results. The SEM is described in figure 1:



Conclusions. This preliminary analysis suggests that inflammation-related genes could have a direct effect (not mediated by FeNO and atopy) on symptom severity in adult asthmatics.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Accordini, L. Calciano, C. Bombieri, G. Malerba, F. Belpinati, M. Ferrari, A. R. Lo Presti, M. Olivieri, P. F. Pignatti, R. de Marco (Verona, Italy). The association among inflammation-related genes, fractional exhaled nitric oxide (FeNO), and symptom severity in adult asthma: A structural equation model (SEM). Eur Respir J 2014; 44: Suppl. 58, 2930

Member's Comments

No comment yet.

Related content which might interest you: Concomitant use of fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) as markers for predicting asthma exacerbation Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Correlation of fractional exhaled nitric oxide (FeNO) and peripheral blood eosinophils (PBE) in refractory asthma Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Domiciliary diurnal variation of fractional exhaled nitric oxide (FeNO) for predicting short-term treatment effect Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Combination of elevated exhaled nitric oxide and serum eosinophil cationic protein identifies asthma patients at risk for exacerbation Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 Associations between fractional exhaled nitric oxide (FeNO), asthma, respiratory symptoms and self-reported allergies in female university students in Kobe, Japan Source: International Congress 2015 – Risk factors and co-morbidities in asthma and COPD Year: 2015 β2-Adrenoceptor polymorphisms and asthma phenotypes: interactions with passive smoking Source: Eur Respir J 2007; 30: 48-55 Year: 2007 Adult asthma, fraction of exhaled nitric oxide (FENO), and lung function Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 Relationships between exhaled nitric oxide and atopic profiles (mono-sensitization/poly-sensitization) in asthmatic patients Source: Annual Congress 2013 –Treatment of asthma Year: 2013 iNOS expression is increased in peripheral airways of asthmatic patients Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 The relationship between the concentration of soluble icam-3 molecules and indicators of nitrosative stress in patients with an exacerbation of COPD Source: International Congress 2014 – Basic and translational research in asthma and COPD Year: 2014 Interaction between airway calibre and exhaled NO: Impact on asthma control assessment Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 Longitudinal analysis between exhaled nitric oxide (FeNO), inflammatory markers (IM) in exhaled breath condensate (EBC), lung function, and control/severity of childhood asthma Source: Annual Congress 2007 - Assessing asthma severity and control in children Year: 2007 Dynamics of the nitric oxide metabolites in the exhaled breath condensate (EBC) in atopic asthma (BA) children receiving various treatment options Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Evaluation of fractional exhaled nitric oxide and peripheral blood eosinophil count as biomarkers in patients with refractory asthma Source: Annual Congress 2013 –Asthma Year: 2013 Repeatability of FeNO measurements with an airway inflammation monitor using the 6 second (6s) and the 10 second (10s) exhalation modes in children 6 to 10 years of age with asthma Source: International Congress 2014 – Airway biomarkers Year: 2014 Domiciliary diurnal variation of fractional exhaled nitric oxide (FeNO) to monitor asthma control Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013 Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)? Source: International Congress 2017 – Lung function testing in different patient categories Year: 2017 Meta analysis of asthma exacerbation rates in adult and pediatric asthmatics managed using fractional exhaled nitric oxide versus standard clinical parameters alone Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016